Danish Study Reveals Flu Vaccine Halves Heart Attack Risk Following Breakthrough Infections

New ECDC research finds that the flu vaccine halves the risk of heart attack and stroke even in patients who get infected, providing vital secondary protection.

By: AXL Media

Published: Apr 3, 2026, 11:12 AM EDT

Source: Information for this report was sourced from European Centre for Disease Prevention and Control (ECDC)

A Secondary Shield Against Cardiovascular Complications

While the primary goal of the influenza vaccine has always been the prevention of infection, new research from the European Centre for Disease Prevention and Control (ECDC) suggests its benefits extend deep into the cardiovascular system. A study led by Croci et al. has demonstrated that the vaccine acts as a vital safety net for those who experience "breakthrough" cases. Even when the vaccine fails to block the virus entirely, it appears to fundamentally alter the body’s inflammatory response, significantly reducing the likelihood of a life-threatening heart attack or stroke in the immediate aftermath of the illness.

Quantifying the Post-Infection Risk Window

The research utilized comprehensive Danish health registry data spanning from 2014 to 2025, tracking over 1,200 adults aged 40 and older. The findings highlight a dangerously sharp rise in hospitalizations during the first seven days following a positive PCR test for influenza. During this initial week, the risk of suffering a first-time stroke increased threefold, while the risk of a heart attack surged fivefold. This dramatic escalation underscores the systemic stress that the influenza virus places on the heart and arteries, particularly in older populations with a median age of 75.

The Halving Effect of Prior Vaccination

The most significant takeaway for public health officials is the protective "halving" effect observed in vaccinated individuals. For patients who had received their seasonal flu shot but still contracted the virus, the added risk of a heart attack or stroke was reduced by 50% compared to their unvaccinated peers. This suggests that the vaccine’s presence in the immune system mitigates the severe physiological triggers—such as extreme inflammation and arterial stress—that typically follow a viral infection, even if it does not prevent the respiratory symptoms of the flu itself.